News Enzyvant gains double fast-track for rare disease drug Switzerland-based biopharma start-up Enzyvant has gained a double fast track status from the FDA for its new rare disease candidate RVT-802.
News Report claims WuXi shared US client IP with China US intelligence services advised the authors of the BIOSECURE Act that that WuXi AppTec shared confidential data on US customers with the Chinese government, according to
Digital Sponsored Innovation as Strategy: Enabling life sciences of the future Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.